MacroGenics provides updates on corporate progress, financial results for 2024, advancing clinical product pipeline.

From GlobeNewswire: 2025-03-20 16:02:38

MacroGenics, Inc. provided updates on recent corporate progress and financial results for 2024. Fully enrolled LORIKEET Phase 2 study of lorigerlimab with docetaxel in mCRPC, initiating LINNET Phase 2 study in ovarian cancer. Advancing novel topoisomerase 1 inhibitor-based ADCs. Discontinuing internal clinical development of vobra duo. Cash position of $201.7 million as of December 31, 2024, with cash runway extended into the second half of 2026. Conference call scheduled for today at 4:30 p.m. ET. MacroGenics focusing on advancing pipeline of clinical product candidates, including lorigerlimab, MGC026, and MGC028.

Enrollment complete in LORIKEET Phase 2 study evaluating lorigerlimab with docetaxel in mCRPC. New LINNET Phase 2 study planned for lorigerlimab in ovarian cancer. Advancing multiple novel topoisomerase 1 inhibitor-based ADCs. Discontinuing internal clinical development of vobra duo. Cash, cash equivalents, and marketable securities at $201.7 million as of December 31, 2024, with cash runway extended to second half of 2026. Conference call scheduled for today at 4:30 p.m. ET regarding recent corporate progress and financial results for 2024.

MacroGenics updates on proprietary investigational programs including lorigerlimab Phase 2 study in mCRPC, LINNET Phase 2 study in ovarian cancer, and novel ADCs. Discontinuing development of vobra duo. Cash position of $201.7 million as of December 31, 2024, with cash runway extended into the second half of 2026. Conference call scheduled for today at 4:30 p.m. ET to discuss recent corporate progress and financial results for 2024.



Read more at GlobeNewswire: MacroGenics Provides Update on Corporate Progress and 2024